Leiden, The Netherlands, 19 April 2024 – Amarna Therapeutics, a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases,  including Type 1 Diabetes Mellitus, today announces the appointment of Aurelia Caparrós as the Company’s new Chief Business Officer (CBO), effective 1st of April 2024.

荷兰莱顿，2024年4月19日讯——Amarna Therapeutics是一家私营生物技术公司，开发针对包括1型糖尿病在内的一系列罕见和流行疾病的转化基因疗法，今天宣布任命Aurelia Caparrós为公司新任首席商务官（CBO），自2024年4月1日起生效。

Aurelia brings more than 25 years of healthcare industry experience with expertise in business development, strategy and global marketing including P&L responsibilities spanning diverse geographies. She held global leadership roles for amongst others Novartis, led multiple enterprise transformation programs and implemented strategic growth initiatives to achieve business goals while fostering the culture of inclusion and enterprise mindset.

Aurelia拥有超过25年的医疗保健行业经验，拥有业务发展、战略和全球营销方面的专业知识，包括跨越不同地区的损益责任。她在诺华等公司担任全球领导职务，领导多项企业转型计划，实施战略增长计划，以实现业务目标，同时培养包容文化和企业心态。

As the new CBO, she will be responsible for driving Amarna's future growth and expansion, both in the Netherlands and Spain. Her key responsibilities will include identifying assets, companies, and areas of interest, designing tailored partnering structures, and securing attractive deals through the entire deal-making process.

作为新的CBO，她将负责推动Amarna在荷兰和西班牙的未来增长和扩张。她的主要职责将包括确定资产、公司和感兴趣的领域，设计量身定制的合作结构，并在整个交易过程中确保有吸引力的交易。

Aurelia will also play a crucial role in promoting Amarna as the partner of choice at business partnering meetings and scientific conferences, as well as supporting the company's investor relations and fundraising activities. 'We are thrilled to welcome Aurelia Caparrós as our new Chief Business Officer,' said Henk Streefkerk, CEO and Medical Director of Amarna Therapeutics BV.

Aurelia还将在推动Amarna成为商业合作会议和科学会议的首选合作伙伴，以及支持公司的投资者关系和筹资活动方面发挥关键作用。”Amarna Therapeutics BV首席执行官兼医疗总监亨克·斯特雷夫克（HenkStreefkerk）说，我们很高兴欢迎奥雷莉亚·卡帕罗斯（AureliaCaparrós）担任我们的新任首席商务官。

'Her exceptional leadership and deep industry expertise will be invaluable as we continue to expand our business and bring our transformative gene therapies to patients in need.' === E N D S === About AmarnaAmarna Therapeutics has developed a groundbreaking non-immunogenic viral platform t.

“随着我们继续扩大业务并将我们的变革性基因疗法带给有需要的患者，她卓越的领导力和深厚的行业专业知识将是无价的。”关于AmarnaAmarna Therapeutics开发了一种开创性的非免疫原性病毒平台t。

Attachment

附件

Aurelia Caparros

Aurelia Caparros